Repare Therapeutics (NASDAQ:RPTX) Upgraded by Bloom Burton to Buy

Bloom Burton upgraded shares of Repare Therapeutics (NASDAQ:RPTX) from an accumulate rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports.

Separately, HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Wednesday, February 21st.

Repare Therapeutics Price Performance

Shares of RPTX opened at $3.15 on Friday. The company has a market capitalization of $116.55 million, a price-to-earnings ratio of -1.41 and a beta of 0.56. Repare Therapeutics has a fifty-two week low of $2.98 and a fifty-two week high of $13.85. The business’s 50-day moving average is $5.30 and its 200-day moving average is $5.73.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). The business had revenue of $13.05 million during the quarter, compared to analyst estimates of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. Equities research analysts expect that Repare Therapeutics will post -2.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repare Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank boosted its position in Repare Therapeutics by 7.0% during the first quarter. Swiss National Bank now owns 39,500 shares of the company’s stock worth $562,000 after purchasing an additional 2,600 shares during the period. JPMorgan Chase & Co. boosted its position in Repare Therapeutics by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after purchasing an additional 1,253 shares during the period. BlackRock Inc. boosted its position in Repare Therapeutics by 1.9% during the first quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after purchasing an additional 8,680 shares during the period. Affinity Asset Advisors LLC boosted its position in Repare Therapeutics by 72.5% during the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock worth $6,677,000 after purchasing an additional 197,127 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Repare Therapeutics by 1.6% during the first quarter. Renaissance Technologies LLC now owns 88,100 shares of the company’s stock worth $1,255,000 after purchasing an additional 1,400 shares during the period. Institutional investors and hedge funds own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.